Rett Syndrome Drug Sparks 132% Upside Potential: JPMorgan

JPMorgan has initiated coverage on Neurogene, a biopharmaceutical company, with an "overweight" rating and a price target of $60 per share. This target implies a potential upside of 132% from recent trading levels. The investment bank's positive outlook is primarily driven by Neurogene's experimental treatment, NGN-401. NGN-401 is a one-time gene therapy administered intracerebroventricularly, utilizing EXACT transgene platform technology. It aims to address Rett syndrome, a rare genetic disorder that predominantly affects women, leading to a loss of physical and motor skills after a period of normal development. Neurogene's stock has experienced a significant decline, down approximately 32% over the past three months, influenced by a broader downturn in biotech stocks and the company's second-quarter financial results, which showed increased research and development costs. However, JPMorgan highlights that the release of new trial data for its Rett syndrome treatment in 2027 is anticipated to be a major catalyst for the stock's performance. This bullish stance aligns with the broader analyst consensus, as all ten analysts covering Neurogene currently recommend a buy or strong buy rating for the stock.